Cargando…

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy

The first US Food and Drug Administration (FDA)- and EMA-approved oncolytic virus has been available since 2015. However, there are no markers available that would predict benefit for the individual patient. During 2007–2012, we treated 290 patients with advanced chemotherapy-refractory cancers, usi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hemminki, Otto, Oksanen, Minna, Taipale, Kristian, Liikanen, Ilkka, Koski, Anniina, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035494/ https://www.ncbi.nlm.nih.gov/pubmed/29989063 http://dx.doi.org/10.1016/j.omto.2018.04.003

Ejemplares similares

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

Analysis of predictive and prognostic factors in 290 patients treated with oncolytic adenoviruses
por: Taipale, Kristian, et al.
Publicado: (2015)

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients
por: Taipale, Kristian, et al.
Publicado: (2018)

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer
por: Liikanen, Ilkka, et al.
Publicado: (2022)

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment
por: Hirvinen, Mari, et al.
Publicado: (2013)

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2015)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Oncolytic Immunotherapy: Where Are We Clinically?
por: Hemminki, Akseli
Publicado: (2014)

Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism
por: Koski, Anniina, et al.
Publicado: (2013)

Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy
por: Farzad, Lisa, et al.
Publicado: (2014)

Portrait of a Leader in Immunotherapeutics: Oncolytic viruses for treatment of cancer
por: Hemminki, Akseli
Publicado: (2012)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment
por: Hemminki, Kari, et al.
Publicado: (2022)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
por: Heiniö, Camilla, et al.
Publicado: (2020)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)

Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus
por: Ahtiainen, Laura, et al.
Publicado: (2010)

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
por: Hemminki, Otto, et al.
Publicado: (2020)

Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses
por: Kanerva, Anna, et al.
Publicado: (2008)

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles
por: Autio, Karoliina, et al.
Publicado: (2014)

Survival in melanoma in the nordic countries into the era of targeted and immunological therapies
por: Tichanek, Filip, et al.
Publicado: (2023)

Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries
por: Tichanek, Filip, et al.
Publicado: (2023)

Survival in Lung Cancer in the Nordic Countries Through A Half Century
por: Tichanek, Filip, et al.
Publicado: (2023)

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements
por: Zitricky, Frantisek, et al.
Publicado: (2023)

Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries
por: Hemminki, Kari, et al.
Publicado: (2022)

Survival in gastric and esophageal cancers in the Nordic countries through a half century
por: Hemminki, Kari, et al.
Publicado: (2023)

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden
por: Hemminki, Kari, et al.
Publicado: (2021)

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years
por: Hemminki, Kari, et al.
Publicado: (2022)

Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century
por: Tichanek, Filip, et al.
Publicado: (2023)

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting
por: Clubb, James H. A., et al.
Publicado: (2023)

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021)

Long-Term Periodic and Conditional Survival Trends in Prostate, Testicular, and Penile Cancers in the Nordic Countries, Marking Timing of Improvements
por: Tichanek, Filip, et al.
Publicado: (2023)

Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas–Long-Term Follow Up
por: Saellstrom, Sara, et al.
Publicado: (2021)

SPECT/CT Imaging of hNIS -Expression after Intravenous Delivery of an Oncolytic Adenovirus and (131)I
por: Rajecki, Maria, et al.
Publicado: (2012)

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
por: Havunen, Riikka, et al.
Publicado: (2018)

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
por: Kudling, Tatiana V., et al.
Publicado: (2022)

Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor
por: Hemminki, Kari, et al.
Publicado: (2021)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Survival in colon and rectal cancers in Finland and Sweden through 50 years
por: Hemminki, Kari, et al.
Publicado: (2021)

Conditional survival in breast cancer up to 10 years in the Nordic countries
por: Zitricky, Frantisek, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gggjifkn0rjp9c7frov4onccqd